RS55495B1 - Miševi koji stvaraju vezujuće proteine koji sadrže vl domene - Google Patents

Miševi koji stvaraju vezujuće proteine koji sadrže vl domene

Info

Publication number
RS55495B1
RS55495B1 RS20161086A RSP20161086A RS55495B1 RS 55495 B1 RS55495 B1 RS 55495B1 RS 20161086 A RS20161086 A RS 20161086A RS P20161086 A RSP20161086 A RS P20161086A RS 55495 B1 RS55495 B1 RS 55495B1
Authority
RS
Serbia
Prior art keywords
human
mouse
gene segment
heavy chain
light chain
Prior art date
Application number
RS20161086A
Other languages
English (en)
Serbian (sr)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Karolina A Meagher
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44543797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS55495(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of RS55495B1 publication Critical patent/RS55495B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20161086A 2010-08-02 2011-08-02 Miševi koji stvaraju vezujuće proteine koji sadrže vl domene RS55495B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36990910P 2010-08-02 2010-08-02
PCT/US2011/046196 WO2012018764A1 (en) 2010-08-02 2011-08-02 Mice that make binding proteins comprising vl domains
EP11741730.3A EP2601298B1 (en) 2010-08-02 2011-08-02 Mice that make binding proteins comprising vl domains

Publications (1)

Publication Number Publication Date
RS55495B1 true RS55495B1 (sr) 2017-04-28

Family

ID=44543797

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20161086A RS55495B1 (sr) 2010-08-02 2011-08-02 Miševi koji stvaraju vezujuće proteine koji sadrže vl domene

Country Status (27)

Country Link
US (7) US9516868B2 (enExample)
EP (3) EP2947151A1 (enExample)
JP (6) JP6146913B2 (enExample)
KR (4) KR102008655B1 (enExample)
CN (4) CN105753979B (enExample)
AU (1) AU2011285919C1 (enExample)
BR (1) BR112013002695B1 (enExample)
CA (2) CA2807282A1 (enExample)
CY (1) CY1118562T1 (enExample)
DK (1) DK2601298T3 (enExample)
ES (1) ES2612459T3 (enExample)
HK (1) HK1217511A1 (enExample)
HR (1) HRP20170322T1 (enExample)
HU (1) HUE031903T2 (enExample)
IL (4) IL315833A (enExample)
LT (1) LT2601298T (enExample)
MX (5) MX345251B (enExample)
MY (1) MY172618A (enExample)
NZ (2) NZ707327A (enExample)
PL (1) PL2601298T3 (enExample)
PT (1) PT2601298T (enExample)
RS (1) RS55495B1 (enExample)
RU (2) RU2750219C2 (enExample)
SG (3) SG10201504971QA (enExample)
SI (1) SI2601298T1 (enExample)
SM (2) SMT201700023T1 (enExample)
WO (1) WO2012018764A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
KR101829691B1 (ko) 2010-02-08 2018-02-19 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
EP2597945B1 (en) 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
IL315833A (en) 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
CN107602696B (zh) 2011-08-05 2022-05-13 瑞泽恩制药公司 人源化的通用轻链小鼠
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
MX355062B (es) 2011-10-17 2018-04-03 Regeneron Pharma Ratones con cadena pesada de inmunoglobulina restringida.
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
EP3912465A1 (en) * 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
WO2013134880A1 (en) 2012-03-14 2013-09-19 Innovative Targeting Solutions Inc. Generating targeted sequence diversity in proteins
EP2825653A4 (en) 2012-03-14 2016-01-20 Innovative Targeting Solutions Inc PRODUCTION OF TARGETED SEQUENCE DIVERSITY IN FUSION PROTEINS
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP3912464A1 (en) 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
PT2840892T (pt) 2013-02-20 2018-07-20 Regeneron Pharma Animais não humanos com sequências da cadeia pesada da imunoglobulina modificada
PT3501272T (pt) * 2013-03-13 2023-03-29 Regeneron Pharma Murganhos que expressam um repertório limitado de cadeia leve de imunoglobulina
MY183572A (en) 2013-03-15 2021-02-26 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
EP3051942B1 (en) 2013-10-01 2020-09-02 Kymab Limited Animal models and therapeutic molecules
FR3011249A1 (enExample) * 2013-10-01 2015-04-03 Kymab Ltd
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
WO2015143406A2 (en) * 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CN107438622A (zh) * 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
EP4414484A3 (en) 2016-02-04 2025-01-15 Trianni, Inc. Enhanced production of immunoglobulins
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
SG10201914014XA (en) 2016-06-03 2020-03-30 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
KR20190074310A (ko) 2016-11-08 2019-06-27 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
CR20190271A (es) 2016-12-07 2019-09-03 Genentech Inc Anticuerpos antitau y métodos de uso
AU2017373884B2 (en) 2016-12-07 2024-11-14 Ac Immune Sa Anti-tau antibodies and methods of their use
JP2020505037A (ja) * 2017-01-19 2020-02-20 オープン モノクローナル テクノロジー，インコーポレイテッド 複数の重鎖免疫グロブリン遺伝子座を有するトランスジェニックげっ歯類由来のヒト抗体
IL270594B2 (en) 2017-05-18 2024-06-01 Regeneron Pharma Cyclodextrin protein drug conjugates
CA3074647A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
CN111601619A (zh) 2017-11-07 2020-08-28 里珍纳龙药品有限公司 用于抗体药物偶联物的亲水性连接体
MA50259A1 (fr) 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
RS66546B1 (sr) 2018-03-24 2025-03-31 Regeneron Pharma Genetički modifikovani miševi ili pacovi za dobijanje terapeutskih antitela protiv peptid‑mhc kompleksa, postupci za njihovo dobijanje i upotrebe
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
JP7590871B2 (ja) 2018-05-09 2024-11-27 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗ｍｓｒ１抗体及びその使用方法
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP2020146310A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146316A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146297A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146314A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146298A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146313A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146307A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146309A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146308A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146317A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146306A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146299A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146318A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146303A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146312A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146305A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146300A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146304A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146301A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146315A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146302A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
AU2021255711A1 (en) 2020-04-16 2022-10-27 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
US20220072141A1 (en) 2020-07-13 2022-03-10 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
US12280124B2 (en) 2020-09-14 2025-04-22 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
AU2023207960A1 (en) 2022-01-12 2024-07-11 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
KR20240137086A (ko) 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
JP2026502348A (ja) 2022-12-21 2026-01-22 リジェネロン ファーマシューティカルズ，インク． Ａｄｃコンジュゲーションのためのトポイソメラーゼｉ阻害剤のプロドラッグおよびその使用方法
WO2025096921A1 (en) 2023-11-03 2025-05-08 Regeneron Pharmaceuticals, Inc. Peptide acids as a glp1r agonist and antibody-drug conjugates thereof

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5075181A (en) 1989-05-05 1991-12-24 Kennametal Inc. High hardness/high compressive stress multilayer coated tool
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
AU8212291A (en) 1990-07-10 1992-02-04 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2835787B2 (ja) 1991-03-22 1998-12-14 キヤノン株式会社 強誘電性液晶素子
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5150584A (en) 1991-09-26 1992-09-29 General Motors Corporation Method and apparatus for detecting low refrigerant charge
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
JPH08503617A (ja) 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Ｌ−セレクチンに反応性のヒト化抗体
DE4309308C1 (de) 1993-03-23 1994-04-14 Siemens Nixdorf Inf Syst Belüftungssystem für Schränke mit stark wärmeerzeugenden elektronischen Funktionseinheiten
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
EP0907726A4 (en) 1996-06-26 2001-11-07 Baylor College Medicine CHROMOSOMAL REORDERING BY INSERTING TWO RECOMBINATION SUBSTRATES
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CN1203922A (zh) 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
AU5043200A (en) 1999-05-27 2000-12-18 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
WO2002012437A2 (en) 2000-08-03 2002-02-14 Schooten Wim Van Production of humanized antibodies in transgenic animals
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
JP4115281B2 (ja) 2001-05-11 2008-07-09 キリンファーマ株式会社 ヒト抗体λ軽鎖遺伝子を含むヒト人工染色体、および子孫伝達可能な該ヒト人工染色体を含む非ヒト動物
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
ATE477280T1 (de) 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
WO2003047336A2 (en) 2001-11-30 2003-06-12 Abgenix, Inc. TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
US20030182675A1 (en) 2002-03-22 2003-09-25 Origen Therapeutics Functional disruption of avian immunoglobulin genes
US20050246782A1 (en) 2002-03-22 2005-11-03 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
FI117110B (fi) 2002-07-05 2006-06-15 Outokumpu Oy Anodin syöttö sulatusreaktoriin
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
EP1639009B1 (en) * 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7205148B2 (en) 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
CN1852925A (zh) 2003-07-15 2006-10-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
HUE028552T2 (en) 2004-02-20 2016-12-28 Woodwelding Ag An implant for implantation into bone tissue and a method for preparing it
DK1776383T3 (da) * 2004-07-22 2014-11-03 Kingdon Craig R Bindingsmolekyler
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
WO2006047367A2 (en) 2004-10-22 2006-05-04 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglubolin expression in non-human transgenic animals
RU2435784C2 (ru) 2006-01-25 2011-12-10 Эрасмус Юниверсити Медикал Сентр Роттердам Получение антител из одних тяжелых цепей в трансгенных животных
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
EP2064325B1 (en) 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
JP2010505418A (ja) 2006-10-02 2010-02-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−４受容体に対する高親和性ヒト抗体
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
EP2626371A1 (en) * 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
CA2697448C (en) 2007-08-30 2019-06-11 The Burnet Institute Dendritic cell marker and uses thereof
TWI563002B (en) 2007-09-26 2016-12-21 Chugai Pharmaceutical Co Ltd Antibody constant region mutant
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2721231C (en) 2008-04-14 2015-10-06 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CA2729095C (en) * 2008-06-27 2018-12-04 Merus B.V. Method for producing a transgenic murine mammal
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
MX2011007660A (es) 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
EP2394159B1 (en) 2009-02-04 2018-09-26 Molecular Innovations Assays for detecting prorenin, and antibodies used therein
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
BRPI1014449A2 (pt) * 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
MY152963A (en) 2009-06-26 2014-12-15 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN101620635A (zh) * 2009-08-07 2010-01-06 中兴通讯股份有限公司 页面数据获取方法及服务器、页面更新方法及服务器
SI2954779T1 (sl) 2009-12-10 2019-06-28 Regeneron Pharmaceuticals, Inc. Miši, ki proizvajajo težkoverižna protitelesa
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
KR101829691B1 (ko) 2010-02-08 2018-02-19 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
CN105695415A (zh) * 2010-06-17 2016-06-22 科马布有限公司 动物模型及治疗分子
KR101970944B1 (ko) 2010-06-22 2019-04-23 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
IL315833A (en) 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
MX375115B (es) 2011-02-25 2025-03-06 Regeneron Pharma Ratones de una desintegrina y metaloproteasa 6 (adam6).
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
US20120310284A1 (en) 2011-06-03 2012-12-06 Royal Oak Industries Polyaxial pedicle screw
CN107602696B (zh) 2011-08-05 2022-05-13 瑞泽恩制药公司 人源化的通用轻链小鼠
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
MX355062B (es) 2011-10-17 2018-04-03 Regeneron Pharma Ratones con cadena pesada de inmunoglobulina restringida.
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
EP3912465A1 (en) 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
SMT202100516T1 (it) 2013-04-16 2021-11-12 Regeneron Pharma Modificazione mirata del genoma di ratto
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物

Also Published As

Publication number Publication date
PT2601298T (pt) 2017-01-09
NZ724003A (en) 2021-03-26
NZ740900A (en) 2023-11-24
KR20200116547A (ko) 2020-10-12
CN118791596A (zh) 2024-10-18
IL258338A (en) 2018-05-31
JP6759303B2 (ja) 2020-09-23
IL224523B (en) 2018-04-30
JP6146913B2 (ja) 2017-06-14
BR112013002695B1 (pt) 2023-01-24
SMT201700023T1 (it) 2017-03-08
RU2750219C2 (ru) 2021-06-24
RU2612903C2 (ru) 2017-03-13
AU2011285919C1 (en) 2015-09-17
SG187673A1 (en) 2013-03-28
RU2017106292A (ru) 2019-01-21
IL315833A (en) 2024-11-01
JP2016054746A (ja) 2016-04-21
SG10201912639SA (en) 2020-02-27
JP7110257B2 (ja) 2022-08-01
US20140130194A1 (en) 2014-05-08
BR112013002695A2 (pt) 2017-03-01
DK2601298T3 (en) 2017-02-27
WO2012018764A1 (en) 2012-02-09
CN113150121A (zh) 2021-07-23
HRP20170322T1 (hr) 2017-04-21
MX363084B (es) 2019-03-07
RU2013109068A (ru) 2014-09-10
JP2020078328A (ja) 2020-05-28
JP7078400B2 (ja) 2022-05-31
US12486335B2 (en) 2025-12-02
EP2947151A1 (en) 2015-11-25
US20140130193A1 (en) 2014-05-08
NZ606824A (en) 2015-05-29
US9516868B2 (en) 2016-12-13
HK1217511A1 (en) 2017-01-13
US20210163628A1 (en) 2021-06-03
CA2807282A1 (en) 2012-02-09
CN105753979B (zh) 2021-05-07
MX350591B (es) 2017-09-11
CN103154255A (zh) 2013-06-12
CN113150121B9 (zh) 2024-11-26
ES2612459T3 (es) 2017-05-17
MX2013001360A (es) 2013-06-28
JP2021119792A (ja) 2021-08-19
SMT201700023B (it) 2017-03-08
KR102008655B1 (ko) 2019-08-08
EP2601298A1 (en) 2013-06-12
KR102306967B1 (ko) 2021-10-01
KR20190095511A (ko) 2019-08-14
IL271804B1 (en) 2024-11-01
SI2601298T1 (sl) 2017-03-31
SG10201504971QA (en) 2015-07-30
EP3960865A1 (en) 2022-03-02
US20170226231A1 (en) 2017-08-10
US10954310B2 (en) 2021-03-23
KR20210118972A (ko) 2021-10-01
US20170223939A1 (en) 2017-08-10
NZ707327A (en) 2017-01-27
CN105753979A (zh) 2016-07-13
AU2011285919B2 (en) 2015-04-30
CY1118562T1 (el) 2017-07-12
MX2018014787A (es) 2023-02-14
KR102163138B1 (ko) 2020-10-08
CN103154255B (zh) 2016-04-06
MX345251B (es) 2017-01-23
EP2601298B1 (en) 2016-11-30
US20120096572A1 (en) 2012-04-19
MY172618A (en) 2019-12-06
IL271804A (en) 2020-02-27
IL258338B (en) 2020-01-30
PL2601298T3 (pl) 2017-03-31
KR102434557B1 (ko) 2022-08-23
MX2023001793A (es) 2023-03-10
HK1181810A1 (en) 2013-11-15
JP2013535213A (ja) 2013-09-12
CA3250882A1 (en) 2025-11-29
LT2601298T (lt) 2017-03-10
IL271804B2 (en) 2025-03-01
US20220177606A1 (en) 2022-06-09
HUE031903T2 (en) 2017-08-28
US9686970B2 (en) 2017-06-27
CN113150121B (zh) 2024-08-16
RU2017106292A3 (enExample) 2020-12-10
JP2018046872A (ja) 2018-03-29
JP2019047805A (ja) 2019-03-28
AU2011285919A1 (en) 2013-02-28
KR20130100277A (ko) 2013-09-10

Similar Documents

Publication Publication Date Title
US12486335B2 (en) Mice that make VL binding proteins
AU2017219079B9 (en) Mice that make binding proteins comprising vl domains
HK40069751A (en) Mice that make binding proteins comprising vl domains
HK1181810B (en) Mice that make binding proteins comprising vl domains
NZ724003B2 (en) Mice that make binding proteins comprising vl domains